Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology

R Greco; M Labopin; M Badoglio; P Veys; JMF Silva; M Abinun; F Gualandi; M Bornhauser; F Ciceri; R Saccardi; A Lankester; T Alexander; AR Gennery; P Bader; D Farge; JA Snowden

doi:10.3389/fimmu.2019.01570

Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology

R Greco, M Labopin, M Badoglio, P Veys, JMF Silva, M Abinun, F Gualandi, M Bornhauser, F Ciceri, R Saccardi, A Lankester, T Alexander, AR Gennery, P Bader, D Farge, JA Snowden

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age

Original language	English
Journal	Frontiers in Immunology
Volume	10
DOIs	https://doi.org/10.3389/fimmu.2019.01570
Publication status	Published - 2019

Access to Document

10.3389/fimmu.2019.01570

http://www.scopus.com/inward/record.url?scp=85069483082&partnerID=8YFLogxK

Fingerprint Dive into the research topics of 'Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology'. Together they form a unique fingerprint.

Cite this

Greco, R., Labopin, M., Badoglio, M., Veys, P., Silva, JMF., Abinun, M., Gualandi, F., Bornhauser, M., Ciceri, F., Saccardi, R., Lankester, A., Alexander, T., Gennery, AR., Bader, P., Farge, D., & Snowden, JA. (2019). Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.01570

Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties : Frontiers in Immunology. / Greco, R; Labopin, M; Badoglio, M; Veys, P; Silva, JMF; Abinun, M; Gualandi, F; Bornhauser, M; Ciceri, F; Saccardi, R; Lankester, A; Alexander, T; Gennery, AR; Bader, P; Farge, D; Snowden, JA.

In: Frontiers in Immunology, Vol. 10, 2019.

Research output: Contribution to journal › Article › peer-review

Greco, R, Labopin, M, Badoglio, M, Veys, P, Silva, JMF, Abinun, M, Gualandi, F, Bornhauser, M, Ciceri, F, Saccardi, R, Lankester, A, Alexander, T, Gennery, AR, Bader, P, Farge, D & Snowden, JA 2019, 'Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology', Frontiers in Immunology, vol. 10. https://doi.org/10.3389/fimmu.2019.01570

Greco, R ; Labopin, M ; Badoglio, M ; Veys, P ; Silva, JMF ; Abinun, M ; Gualandi, F ; Bornhauser, M ; Ciceri, F ; Saccardi, R ; Lankester, A ; Alexander, T ; Gennery, AR ; Bader, P ; Farge, D ; Snowden, JA. / Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties : Frontiers in Immunology. In: Frontiers in Immunology. 2019 ; Vol. 10.

@article{8dab746af88f4d95ab281aad2117fa87,

title = "Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology",

abstract = "Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age ",

author = "R Greco and M Labopin and M Badoglio and P Veys and JMF Silva and M Abinun and F Gualandi and M Bornhauser and F Ciceri and R Saccardi and A Lankester and T Alexander and AR Gennery and P Bader and D Farge and JA Snowden",

year = "2019",

doi = "10.3389/fimmu.2019.01570",

language = "English",

volume = "10",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties

T2 - Frontiers in Immunology

AU - Greco, R

AU - Labopin, M

AU - Badoglio, M

AU - Veys, P

AU - Silva, JMF

AU - Abinun, M

AU - Gualandi, F

AU - Bornhauser, M

AU - Ciceri, F

AU - Saccardi, R

AU - Lankester, A

AU - Alexander, T

AU - Gennery, AR

AU - Bader, P

AU - Farge, D

AU - Snowden, JA

PY - 2019

Y1 - 2019

N2 - Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age

AB - Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age

U2 - 10.3389/fimmu.2019.01570

DO - 10.3389/fimmu.2019.01570

M3 - Article

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

ER -